PLOS BLOGS Book Corner
Blogger Tweets
sethmnookin: One of my favorite canals. “@BoraZ: Mary Roach Takes A Trip Down the Alimentary Canal: http://t.co/Gwpwvx4b1A”
EmilyAnthes: +1 Somebody should Storify that RT @ShipLives I highly recommend folks go to @umairh's feed and check out his epic rant. Great stuff
TravisSaunders: Thesis lit review has been submitted for publication. Now all that's left is the general discussion and I'm done!
hillaryrosner: Brilliant. RT @edyong209: . @YourTitleSucks is hilarious.
stevesilberman: The night Dylan dropped by Allen Ginsberg's apartment with his new album. http://t.co/66jeBSeNL1
daniel_lende: RT @Dirk57: Addiction is not a typical disease, nor a simple matter of choice. Maybe "disease model" should become "biochemical model."
mfenner: @0Albogami I can't recommend specific reference manager for iPad.
MrEpid: @purdy_eve Yes! I will not forget our @MenchiesKTown #tweetup with @bob_connelly. Hopefully when it's actually warm again :-/ Enjoy freedom!
BethSkw: @StrangeSource @PLOSONE Congrats!
Jason_Reads: RT @AmasianV: My @plosblogs post for Asian-Pacific American Heritage Month *and* Hepatitis Awareness Month http://t.co/UJ27HG1qa8 #hepaware…
jeancflanagan: @hildabast tell me how it goes! I planned on it but had to much work.
Author: Jessica Wapner
MATH and Tumors
Category: cancer
Tagged cancer, Edmund Mroz, Massachusetts General Hospital, math, tumor heterogeneity
Leave a comment
Indian Court Rules in Favor of Generic Gleevec
Category: cancer, drug patents
Tagged generic drugs, Gleevec, imatinib mesylate, Novartis
Leave a comment
For a Song: Bartering Music for Healthcare
Category: Healthcare Affordability
Tagged Arthur Chandler, health insurance, Joe Concra, O+ Festival
Leave a comment
The Battle Over Generic Drugs in India (and elsewhere)
Category: cancer, drug patents, Ethics, generic drugs, Healthcare disparities
Tagged antiretroviral drugs, Cipla, CML, erlotinib, generic drugs, Gleevec, HIV/AIDS, imatinib, India, lung cancer, Novartis, patents, Roche, Tarceva, TRIPS
Leave a comment
